GAO Flags How a REMS May Slow Generics

Drug Industry Daily
A A
Generic drugmakers have acknowledged to the GAO that their inability to access samples of reference drugs because of distribution limitations under certain risk evaluation and mitigation strategies (REMS) delayed or discouraged them from developing generic drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily